Compare AbCellera Biologics Inc (ABCL) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Dollar General Corp. — how do they compare? AbCellera Biologics Inc trades at $9.12 (market cap $2.85B), while Dollar General Corp. trades at $120.1 (market cap $27.00B). The key difference: Dollar General Corp. is far larger — about 9.5× AbCellera Biologics Inc's market cap, and Dollar General Corp. pays a 1.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | DG | |
|---|---|---|
Market Cap | $2.85B | $27.00B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $156.26 |
52-Week Low | $2.78 | $95.94 |
Enterprise Value | $2.45B | $41.45B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Dollar General (DG) trades at $126.59, down 0.69% on the day, with strong technical momentum indicated by bullish moving averages and oversold RSI conditions. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.00 exceeding expectations of $1.89, while maintaining solid profitability metrics including 18.91% ROE. Recent cash flow trends show improvement with 2025 net cash flow of $395 million, and the balance sheet reflects declining debt-to-asset ratios from 22.73% to 20.03% year-over-year.
The outlook remains positive with analyst consensus favoring Buy ratings (52%) and a $128.45 price target offering modest upside. Key opportunities include consumer trade-down benefits and margin improvement, while risks involve competition from Walmart and Amazon, market saturation concerns, and ongoing cost pressures. The stock presents a value proposition with attractive P/S (0.65) and P/E (17.91) multiples relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
